[The use of gonadotropin-releasing hormone agonist (GnRH-a) dipherelin 3,75 mg for in vitro fertilization program].
For the purpose of optimizing the superovulation stimulation and improving clinical outcome, the gonadotropin-releasing hormone (GnRH-a) agonist were successfully used in the in vitro fertilization program. Under observation were 200 women of the reproductive age with the average length of sterility 7,6+/-4,1 years. The causes of sterility were as follows: tubo-peritoneal factor 84 (42%), endometriosis 54 (27%), PCOS 24 (19%), unknown infertility 38 (19%). After the transvaginal puncture, the fertilization rate constituted 136 (67,8%). Out of 200 patients the clinical pregnancy occurred in 58 (28,7%). The obtained results indicate that the use of the GnRH agonist dipherelin 3,75 mg--in the in vitro fertilization program is an effective means of achieving the desired pregnancy.
Khonelidze
N
N
Zhordania Research Institute of Human Reproduction, Tbilisi, Georgia.
Tsagareishvili
G
G
Koiava
M
M
Osidze
K
K
D000328:Adult; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D005307:Fertilization in Vitro / Q000379:methods*; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007246:Infertility / Q000188:drug therapy*; D011247:Pregnancy; D015397:Program Evaluation; D016896:Treatment Outcome
D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone